Bristol Boosts ImClone Funding To Accelerate Erbitux Development
Bristol will invest an additional “several hundred million dollars” toward Erbitux late-stage clinical trials in brain, breast, bladder, esophageal, gastric and lung cancers.
Bristol will invest an additional “several hundred million dollars” toward Erbitux late-stage clinical trials in brain, breast, bladder, esophageal, gastric and lung cancers.